Evidence map›Paper›PMID 35062908›Full record

ArticleBMC cancer2022

Fibrinogen/albumin ratio as a promising predictor of platinum response and survival in ovarian clear cell carcinoma.

Wei Chen, Boer Shan, Shuling Zhou, Huijuan Yang, Shuang Ye

Open access · goldAbstract readEvaluation Study
PubMed Full text at PMC Publisher
In one paragraph

Article in BMC cancer, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers, 3 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
11citing papers in PubMed, 3 pooled it
5.2field-weighted citation impact, top 4% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

11 citing papers in PubMed, 3 syntheses or guidelines pooled it, 28 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
  9. Article
  10. Article
  11. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors at 3 institutions in 1 country.

Wei Chen *Department of Gynecologic Oncology, Fudan University Shanghai Cancer Center, Shanghai, China.
Boer Shan *Department of Gynecologic Oncology, Fudan University Shanghai Cancer Center, Shanghai, China.
Shuling ZhouDepartment of Oncology, Shanghai Medical College, Fudan University, Shanghai, 200032, China.
Huijuan YangDepartment of Gynecologic Oncology, Fudan University Shanghai Cancer Center, Shanghai, China. huijuanyang@hotmail.com.
Shuang YeDepartment of Gynecologic Oncology, Fudan University Shanghai Cancer Center, Shanghai, China. mendy_ye@126.com.
Fudan University Shanghai Cancer Center · CNShanghai Medical College of Fudan University · CNMinhang District Central Hospital · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundThis study aims to evaluate the role of the fibrinogen/albumin ratio (FAR) in predicting platinum resistance and survival outcomes of patients with ovarian clear cell carcinoma (OCCC).

methodsCoagulation function and D-dimer, serum albumin, CA125 and HE4 levels were measured before surgery in OCCC patients undergoing initial surgery in our institution. FAR was calculated as fibrinogen/albumin level. The correlation between these indicators and clinicopathological features, platinum response, and survival outcomes was further analyzed. The Kaplan-Meier method and multivariable Cox regression model were used to assess the effects of FAR on progression-free survival (PFS) and overall survival (OS).

resultsAdvanced stage patients accounted for 42.1% of the 114 participants. Optimal cytoreductive surgery was achieved in 105 patients, and the complete resection rate was 78.1%. FAR was associated with tumor stage, residual tumor and platinum response. A receiver operating characteristic curve for predicting platinum response showed that the optimal cutoff point of the FAR was 12%. The sensitivity was 73.3% and the specificity was 68.2%. In multivariate analysis, FAR ≥12% (HR = 4.963, P = 0.002) was an independent risk factor for platinum resistance. In addition, FAR and D-dimer proved to be independent negative factors for outcomes including both PFS and OS. The median follow-up time was 52 months. A high FAR (≥ 12%) showed a stronger correlation with poor OS and PFS in the subgroup analysis of advanced and completely resected patients.

conclusionsThe FAR might be a potential preoperative biochemical marker for predicting treatment response and oncological outcomes in OCCC patients.

Indexed as

Adenocarcinoma, Clear CellAdultAntineoplastic AgentsBiomarkers, TumorCA-125 AntigenCytoreduction Surgical ProceduresDrug MonitoringFemaleFibrin Fibrinogen Degradation ProductsFibrinogenHumansMembrane ProteinsMiddle AgedOvarian NeoplasmsOvaryPlatinum CompoundsAntineoplastic AgentsBiomarkers, TumorCA-125 AntigenFibrin Fibrinogen Degradation Productsfibrin fragment DFibrinogenMembrane ProteinsMUC16 protein, humanPlatinum CompoundsSerum AlbuminWAP Four-Disulfide Core Domain Protein 2WFDC2 protein, humanClear cell carcinomaFibrinogen/albumin ratioOvarian neoplasmsPlatinum resistanceSurvival

Identifiers

PMID35062908
PMCPMC8780809
OpenAlexW4206960577

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.